Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial - European Urology Oncology
1616-Bladder/Urothelial neoad ddMVAC (dd methotrexate vinBLASTine DOXOrubicin ciSplatin) | eviQ
Treatment Administration Schedule: Dose-Dense MVAC (every 14 days for... | Download Table
PT0 after NAC: Implications for Bladder Sparing and Prognosis
Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease | MDedge Hematology and Oncology
Randomized phase III trial of dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as perioperative chemotherapy for patients with MIBC. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints -
Selecting and Sequencing Therapy in Advanced Urothelial Carcinoma: Navigating a Dynamic Landscape
GETUG on Twitter: "VESPER (NCT01812369) phase III trial in bladder cancer comparing cisplatin-gemcitabine and dose-dense MVAC in perioperative setting. Preliminary results at ASCO GU 2020 https://t.co/kpjFOQLmap" / Twitter
Neoadjuvant Dose-Dense MVAC Demonstrates Superior Survival Outcomes in Bladder Cancer
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ...
Treatment Administration Schedule: Dose-Dense MVAC (every 14 days for... | Download Table
Understanding Systemic Chemotherapy Options in Bladder Cancer Part II: Chemotherapy Candidacy & Side Effects
A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer - Clinical and Translational Radiation Oncology
Dose-dense MVAC vs gemcitabine and cisplatin tied to better survival in bladder cancer patients | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
1438-Bladder/Urothelial neoadjuvant MVAC (methotrexate vinBLASTine DOXOrubicin ciSplatin) SUPERSEDED | eviQ
Significant PFS Improvement at 3 Years with Neoadjuvant dd-MVAC
Pierre Blanchard, MD on Twitter: "PRACTICE CHANGING @GETUG_Unicancer TRIAL FOR BLADDER CANCER at #ESMO21 Dose dense MVAC improves PFS & OS over Gem-Cisplatin as periop treatment (neoadj 89%; adj 11%) chemo in
Bladder cancer
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study - Clinical Genitourinary Cancer
Treatment Administration Schedule: Dose-Dense MVAC (every 14 days for... | Download Table
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial | Journal of Clinical ...
Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience | PLOS ONE
Neoadjuvant Chemotherapy for Bladder Cancer
Treatment Administration Schedule: Dose-Dense MVAC (every 14 days for... | Download Table
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ...
EAU15 - Poster: Neoadjuvant dose-dense MVAC for muscle invasive bladder cancer; efficacy and safety compared to the traditional MVAC regimen
Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine–cisplatin and high dose-intensity MVAC | SpringerLink
